{
    "clinical_study": {
        "@rank": "23230", 
        "arm_group": {
            "arm_group_label": "Alprostadil, Control", 
            "arm_group_type": "Experimental", 
            "description": "Alprostadil  interventions: Alprostadil  40 ug + 1cc/kg/hr  normal  salin  6  hour  before  and  after  angiography  AND  Control interventions:Normal  salin  1cc/kg/hr  before  and  after  angiography"
        }, 
        "brief_summary": {
            "textblock": "The  aim of  this  prospective, randomized, controlled  study  is  to  investigate  the\n      effect  of  pretreatment  with  intravenous  Alprostadil  on  the  incidence  of  CIN  in\n      a  high-risk  population  of  patients  with  both  type  2  diabetes  mellitus (T2DM)  and\n      CKD  undergoing  coronary  angiography, and  evaluate  the  influence  of  such  potential\n      benefit  on  short-term  outcome."
        }, 
        "brief_title": "Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kidney Diseases", 
            "Diabetes Mellitus", 
            "Acute Kidney Injury", 
            "Kidney Failure, Chronic", 
            "Renal Insufficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Kidney Diseases", 
                "Acute Kidney Injury", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The  number  of  cardiac  angiography  and  percutaneous  coronary  interventions (PCI) has\n      increased  steadily  in  recent  years. This  has  resulted  in the  increasing  incidence\n      of  contrast-induced  nephropathy (CIN). Major  risk  factors  for  CIN  include  older\n      age, diabetes  mellitus (DM), chronic  kidney  disease (CKD).\n\n      The  aim of  this  prospective, randomized, controlled  study  is  to  investigate  the\n      effect  of  pretreatment  with  intravenous  Alprostadil  on  the  incidence  of  CIN  in\n      a  high-risk  population  of  patients  with  both  type  2  diabetes  mellitus (T2DM)  and\n      CKD  undergoing  coronary  angiography, and  evaluate  the  influence  of  such  potential\n      benefit  on  short-term  outcome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient  that  underwent  coronary  angiography\n\n          -  T2DM\n\n          -  CKD  stages  2  and  3, eGFR  30  to  89ml/min  per  1.73m2\n\n          -  Alprostadil  naive, or  not  on  Alprostadil  treatment  for  at      least  14  days\n\n          -  Withdrawal  metformin  or  aminophylline  for  48h  before  angiography\n\n        Exclusion Criteria:\n\n          -  serum  Cr. More  than  3  mg/dl\n\n          -  electrolyte  and  acid-base  imbalance\n\n          -  pulmonary  edema\n\n          -  allergy  to  Alprostadil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722513", 
            "org_study_id": "NCT20120312"
        }, 
        "intervention": {
            "arm_group_label": "Alprostadil, Control", 
            "description": "control:Normal  salin  1cc/kg/hr  before  and  after  angiography", 
            "intervention_name": "Alprostadil \ufe60control", 
            "intervention_type": "Drug", 
            "other_name": [
                "Drug: Alprostadil", 
                "lipo-alprostadil", 
                "Prostaglandin E1", 
                "Drug: normal  salin"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Alprostadil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Contrast Induced Nephropathy", 
        "lastchanged_date": "November 6, 2012", 
        "link": [
            {
                "description": "Shanghai Tenth People's Hospital", 
                "url": "http://www.shdsyy.com.cn"
            }, 
            {
                "description": "State Food and Drug Administration ,China", 
                "url": "http://www.sda.gov.cn/WS01/CL0001/"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200072"
                }, 
                "name": "Department of Cardiology, Shanghai Tenth People's Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization", 
        "overall_official": {
            "affiliation": "Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School  of  Medicine", 
            "last_name": "Ya-Wei Xu, MD, FACC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An  absolute  increase  in  SCr >=0.5mg/dL\uff08>=44.2\u03bcmmol/L\uff09or  a >= 25%  increase  in  SCr  from  baseline  to  72h  after  the  procedure", 
            "measure": "Primary Outcome", 
            "safety_issue": "Yes", 
            "time_frame": "72 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722513"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai 10th People's Hospital", 
            "investigator_full_name": "Ya-Wei  Xu", 
            "investigator_title": "MD   FACC", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "10607766", 
            "citation": "Koch JA, Plum J, Grabensee B, M\u00f6dder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000 Jan;15(1):43-9."
        }, 
        "secondary_outcome": {
            "description": "The  composite  of  hospitalization  for  aggravated  renal  function, acute  renal  failure, dialysis  or  hemofiltration, aggravated  at  least  1  class  of  heart function, acute  left  ventricular  failure  or  death  from  all  causes.", 
            "measure": "Secondary Outcome", 
            "safety_issue": "Yes", 
            "time_frame": "30 d"
        }, 
        "source": "Shanghai 10th People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai 10th People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}